LGALS1 and prostate cancer: Corapi et al. further demonstrated an exciting scenario where the high levels of Gal-1 produced by prostate cancer (PCa) cells are not enough to evade immune attack; tumors require additional licensing by lymphocyte endogenous Gal-1 to be efficiently immune-suppressive [151].